Cell surface marker CD9 has been reported to play a role in inhibiting trophoblastic cell invasion. Since the invasive properties of cancer cells may resemble those of trophoblasts, we decided to investigate the role of CD9 in the invasion of endometrial cancer cells. In normal human endometrium, CD9 was found to be constitutively expressed on epithelial cells, as reported previously. While epithelial cells of endometrial hyperplasia (n ⍧ 5) were also positive for the expression of CD9, endometrial adenocarcinomas (n ⍧ 15) showed reduced expression. In order to clarify the significance of this reduced CD9 expression in endometrial cancer, an in-vitro invasion assay system was used to assess the effect of anti-CD9 monoclonal antibody (mAb) on the invasive properties of endometrial cancer cell line. Anti-CD9 mAb significantly enhanced invasion of the RL95-2 and Ishikawa cell lines, without affecting cell proliferation. Since CD9 is associated with the integrin subunits β 1 , α 3 and α 6 in human endometrium, we investigated the functional relationship between CD9 and these integrins in the RL95-2 cell line. Monoclonal antibodies against the integrins β 1 , α 3 and α 6 inhibited RL95-2 cell invasion. However, anti-CD9 mAb continued to show a stimulatory effect on RL95-2 cell invasion after treatment with anti-integrin α 3 mAb. In contrast, the anti-CD9 mAb had no effect after treatment with the mAb for integrins α 6 and β 1 . These findings indicate that CD9 is involved in regulating the invasive properties of endometrial carcinoma cells and that this effect is partially mediated by integrin subunits α 6 and β 1 . Thus, CD9 appears to be involved in the prevention of endometrial cancer invasion.
Introduction
trophoblast cells differs between early pregnancy and term; i.e. the expression of CD9 in the extravillous trophoblast In a recent study, we found that a cluster of differentiation invading the endometrium in early pregnancy is weak, but that (CD) antigen 9 molecules was expressed on the human in the placental bed and chorionic laevae of the term placenta endometrial epithelial cells throughout the menstrual cycle is very intense. These results imply that the intense expression (Park et al., 2000) . The CD9 molecule is a 24-27 kDa of CD9 tends to be associated with the extravillous trophoblasts glycoprotein, originally reported to be expressed on the cell which have ceased migration or invasion into the endometrium. surface of haematopoietic cells, e.g. pre-B-lymphocytes, Furthermore, it has been shown that anti-CD9 mAb significplatelets and activated T-lymphocytes (Kersey et al., 1981;  antly enhanced the invasion of BeWo cells, a trophoblast like Boucheix et al., 1983) . A number of studies using anti-CD9 choriocarcinoma cell line, in vitro (Hirano et al., 1999b) . These monoclonal antibodies (mAb) have shown that the CD9 findings suggest that CD9 may have an important role in molecule is involved in the functions of haematopoietic cells, inhibiting cell invasion. e.g. platelet activation, aggregation and adhesion, neutrophil Many elements of trophoblast invasion resemble the events adhesion and pre-B cell adhesion (Jennings et al., 1990;  that occur during malignant tumour cell invasion (Aplin, 1991; Masselis-Smith and Shaw, 1990; Forsyth, 1991) . It has also Tabibzadeh and Babaknia, 1995) , suggesting that CD9 may been reported that the CD9 molecule is involved in Schwann also be involved in regulating cancer cell invasion. Therefore, cell migration and adhesion (Hadjiargyrou and Patterson, in this study, we examined the expression of CD9 in both 1995).
endometrial hyperplasia and in endometrial cancer, and We have found that CD9 is expressed on the extravillous observed a reduced expression of CD9 in human endometrial trophoblasts in the cell columns of first trimester human cancer in comparison with normal endometrial epithelium. placenta, which then differentiate into invading extravillous This observation led us to investigate the effect of anti-CD9 trophoblasts (Hirano et al., 1999a) . On the other hand, CD9 mAb on the cell proliferation and invasive properties of is not expressed in villous trophoblasts of the human placenta.
endometrial cancer using endometrial cancer cell lines, e.g. RL95-2 (Way et al., 1983) and Ishikawa (Nishida et al., 1985) . Moreover, the intensity of CD9 expression in extravillous
Materials and methods
Perma Fluor Aqueous Mounting Medium (Immunon, Pittsburgh, PA, USA), which reduces fluorescence fading, and examined under a Tissues fluorescence microscope (Nikon, Tokyo, Japan). Specimens of endometrial hyperplasia were obtained from five patients Flow cytometry aged 44-81 years; specimens of endometrial carcinoma were obtained from 15 patients aged 39-79 years. The endometrial hyperplasias
The dispersed RL95-2 and Ishikawa cells (2ϫ10 5 ) were centrifuged consisted of one simple and four atypical hyperplasias. The 15 cases and incubated at 4°C for 30 min with 10 ml of the anti-CD9 mAb of endometrial carcinoma consisted of 10 in stage I, two in stage III, (ALB-6, 100 µg/ml), the anti-integrin mAb (PIB5 for α 3 , OG-1 for two in stage IV and one recurrent according to the International α 6 , or P4C10 for β 1 subunit; 100 µg/ml each), or the anti-TNP mAb Federation of Gynecology and Obstetrics (FIGO) classification. Histo-(negative control, 100 µg/ml). The cells were washed twice with logically, all carcinomas were classified as endometrioid, with six Hanks' balanced salt solution (HBSS), and incubated with 20 ml of being well differentiated (G1), five moderately differentiated (G2), FITC-conjugated rabbit anti-mouse immunoglobulins (diluted to 1:40) and four poorly differentiated (G3). None of the patients received at 4°C for 30 min in the dark. The cells were then washed three any hormonal or drug therapy. This study was approved by the ethical times and resuspended in HBSS after the second antibody incubation, committee of Kyoto University and preoperative informed consent and the number of viable cells was analysed using flow cytometry was obtained from all patients.
(FACScan; Becton Dickinson Immunocytometry Systems, Mountain View, CA, USA). Three independent experiments were performed. Antibodies Invasion assay Two mouse anti-human CD9 monoclonal antibodies (mAbs), TP-82
The invasion assay was carried out as previously described (Hirano [immunoglobulin G 1 (IgG1) class] and ALB-6 (IgG1 class), were et al., 1999b) . The cell lines were cultured on cell culture inserts purchased from Nichirei Co (Tokyo, Japan) and Cosmo Bio Co Ltd (6.4 mm in diameter of membrane; Becton Dickinson Labware, NJ, (Tokyo, Japan) respectively (Boucheix et al., 1983; Higashihara USA) containing polyethylene terephthalate membranes with 8 µm et al., 1985) . An anti-human CD9 mAb (SYB-1) a generous gift from diameter pores, which were placed in each well of a 24-well tissue Dr C.Boucheix and Dr E.Rubinstein, INSERM U268, Hôpital Paul culture plate (Falcon, Becton Dickinson Labware). Prior to cell Brousse, France (Boucheix et al., 1983 ). An unrelated mouse anticulture, the upper surface of the filters was coated with cold Matrigel trinitrophenyl (anti-TNP) mAb (IgG1 class) and an anti-mouse (100 µg/cm 2 , Collaborative Research Co, Bedford, MA, USA) and erythroid cell mAb, TER199 (IgG2a class) were used for negative air-dried aseptically. The inserts were rehydrated with 100 µl of warm controls (Tsujimura et al., 1990; Ikuta et al., 1997) .
Dulbecco's modified Eagle's medium (DMEM) for 2 h. A total of Two mouse anti-human integrin α 3 mAb, 11G5 (IgG1 class) 60 000 viable RL95-2 or Ishikawa cells suspended in 200 ml of DMEM and PIB5 (IgG1 class), were purchased from Serotec (Oxford, UK) supplemented with 10% fetal calf serum (FCS) were inoculated into and Gibco-BRL (Gaithersburg, MD, USA) respectively. The mouse the culture inserts (upper chamber), and 700 ml of medium was anti-human integrin α 6 mAb OG-1 (IgG1 class) was developed in added to the culture well (lower chamber). The anti-CD9 mAb our laboratory (Fujiwara et al, 1993) . The rat anti-human integrin α 6 (ALB-6; 0, 0.05, 0.5, and 5 µg/ml) or the control antibody (anti-TNP, mAb GoH3 (IgG2a class) was purchased from Serotec. Three mouse 5 µg/ml) was then added into the culture medium (DMEM with 10% anti-human integrin β 1 mAb: DF5 (IgG1 class), 3S3 (IgG1 class) and FCS). After 48 h of culture period, the upper surface of the filter was P4C10 (IgG1 class) were purchased from Affinity Research Products 'scrubbed' three times with a cotton swab. Cells remaining on the Ltd (Nottingham, UK), Serotec and Gibco-BRL. ALB-6, PIB5, lower surface of the 'scrubbed' filter were fixed in methanol for GOH3, and 3S3 reportedly have functional blocking effects on their 10 min at room temperature, and stained with haematoxylin. For own antigens (Boucheix et al., 1983; Carter et al., 1990; Sonnenberg quantification, the cells that had migrated to the lower surface were et al Gao et al., 1995) . Fluorescein isothiocynate (FITC)-counted under a microscope in five pre-determined fields at ϫ200 conjugated rabbit anti-mouse immunoglobulins or FITC-conjugated magnification. The assay was performed in triplicate chambers. Five goat anti-rat immunoglobulins were purchased from Dako (Glostrup, independent experiments of the cell culture lines were performed. Denmark) and were used as the second antibodies for histochemistry.
In RL95-2 cells, the effects of the anti-integrin mAb (P1B5 for A horseradish peroxidase (HRP)-conjugated rabbit anti-mouse subunit α 3 , GoH3 for subunit α 6 , or 3S3 for subunit β 1 ) (0, 1.0, and immunoglobulin (Dakopatts, Glostrup, Denmark) was used as the 5.0 µg/ml) on invasion were examined. Furthermore, the effect of second antibody for Western blotting.
the anti-CD9 mAb (ALB-6) on RL95-2 cell invasion was also examined in the presence of the anti-integrin α 3 , α 6 , or β 1 mAb.
Indirect immunofluorescence staining
Immunohistochemical analysis was performed as described elseAssessment of cellular proliferation where (Fujiwara et al., 1993) with minor modifications. Individual
To investigate the effect of ALB6 (anti-CD9) on RL95-2 and specimens were embedded in OCT compound (Tissue-Tec; Miles Ishikawa cell proliferation, these cells (6ϫ10 4 cells) were suspended in Scientific, Naperville, IL, USA), snap-frozen in liquid nitrogen and DMEM with 10% FCS and plated onto Matrigel-coated (100 µg/cm 2 stored at -80°C. Frozen tissues were sliced to a thickness of 7 µm as described above) or non-coated 96-well polystyrene dishes at with a cryostat microtome (Cryocut 1800, Reichert-Jung, Heidelberg, 200 ml/well. The anti-CD9 mAb (ALB-6; 0, 0.05, 0.5, and 5 µg/ml) Germany), immediately air-dried on Neoplene (Nisshin EM, Tokyo, or the control mAb (5 µg/ml) were then added to the culture medium, Japan)-coated glass slides and fixed in acetone at -20°C for 5 min.
and the cells were cultured in triplicate. After 2 days of culture, the The slides were either examined immediately or stored at -20°C cultured cells were dispersed with 0.05% trypsin (Difco Laboratories, until use. The slides were incubated with anti-CD9 monoclonal Detroit, MI, USA) and 0.02% EDTA, and Trypan Blue staining was antibodies, TP-82 (5 mg/ml) and ALB-6 (5 µg/ml) or the anti-TNP used to count the number of viable cells. mAb (5 µg/ml), for 30 min at room temperature. After washing in Affinity chromatography and Western blotting phosphate-buffered saline (PBS), they were incubated with FITCconjugated second antibody (diluted 1:40), for 30 min at room Affinity chromatography and Western blot analysis were performed as described previously (Hirano et al. 1999a ). RL95-2 cells (4ϫ10 7 ) temperature in the dark. The slides were then washed, mounted with were homogenized in 5 ml of 40 mmol/l phosphate buffer, pH 7.3, a dose-dependent manner (Figure 3) . The invasiveness of containing 150 mmol/l NaCl, 1 mmol/l CaCl 2 , 1 mmol/l MgCl 2 , 1% RL95-2 and Ishikawa cells was enhanced by 230 and 155% CHAPS and protease inhibitors including p-amidinophenylmethanesrespectively by anti-CD9 mAb (ALB-6) at a concentration of ulphonylfluoride hydrochloride (0.25 mg/ml), 10 mg/ml leupeptin 0.5 mg/ml. The control anti-TNP antibody had no effect on (Peptide Institute Inc, Osaka, Japan), and 10 mg/ml pepstatin (Peptide invasion by either RL95-2 or Ishikawa cells. Institute). After centrifugation (9000 g for 30 min), the concentration On the other hand, anti-CD9 mAb did not affect cell of CHAPS in the lysate was reduced by dilution to 0.3%. The lysate proliferation of RL95-2 or Ishikawa cells for 2 days in either was then passed through a column containing 10 ml of anti-TNPMatrigel-coated or non-coated dishes (data not shown).
conjugated Affigel 10 (Bio-Rad Laboratories, Hercules, CA, USA, 2 mg IgG/ml gel) at 4°C to remove non-specifically bound compounds.
Effect of anti-integrins α 3 , α 6 and β 1 mAbs on cell
The through-pass fractions were incubated with 0.2 ml of anti-CD9 invasion of RL95-2 cells (TP-82, 100 mg IgG/ml gel), anti-integrin α 3 (11G5, 100µ g IgG/ml gel) or α 6 -conjugated Affigel 10 (OG-1, 200 mg IgG/ml gel) at 4°C
In order to clarify the functional association of CD9 with for 2 h. After thorough washing of the gels, the purified antigens and integrin α 3 , α 6 and β 1 , the effect of anti-CD9 mAb on the their associated proteins were eluted with a sample buffer and invasion by RL95-2 cells was examined in the presence of transferred after 12% sodium dodecyl sulphate-polacrylamide gel blocking mAbs against these integrins. Anti-integrin α 3 mAb electrophoresis (SDS-PAGE) (non-reduced conditions) onto a poly-(PIB5), α 6 mAb (GoH3), and β 1 mAb (3S3) reduced the vinylidine difluoride (PVDF) membrane. The membranes were stained number of invading RL95-2 cells. While the anti-CD9 mAb with anti-CD9 mAb (SYB-1), the anti-integrin β 1 mAb (DF5), or the ALB-6 enhanced RL95-2 cell invasion in the presence of the control mAb (anti-TNP) as described earlier.
anti-integrin α 3 mAb, it had no effect on RL95-2 cell invasion
Statistical analysis
following treatment with the anti-integrin α 6 and β 1 mAbs (Figure 4 ).
The data are expressed as means Ϯ SEM, and were analysed by the two-tailed paired t test for pairwise comparisons or the one-way Association of CD9 with integrin α 3 , α 6 and β 1 in the analysis of variance, followed by Scheffe's F test for multiple comparisons.
endometrium and in RL95-2 cells
Western blot analysis of the proteins purified from the RL95-2 cells by anti-CD9 mAb (TP-82) detected integrin β 1 as a
Results

protein band at 110 kDa (Figure 5, Lane 4), which is compatible Immunohistochemical analysis of CD9 expression in
with the findings of the Western blotting analysis using the human endometrium, endometrial hyperplasia and whole lysate of human endometrial tissue (Park et al., 2000) .
endometrial cancer
In the proteins purified with anti-integrin α 3 (11G5) and α 6 In normal endometrium, a high level of CD9 antigen was (OG-1) mAbs from the RL95-2 cells, CD9 was clearly detected detected on the cell surface of luminal and glandular epithelial as a protein band at 26.5 kDa ( Figure 5 , lanes 2 and 3), cells ( Figure 1A-C ). There were no significant differences in indicating that these integrins were associated with CD9. the intensity of expression of CD9 on epithelial cells throughout This is also compatible with findings from whole lysate of the menstrual cycle, as reported previously (Park et al., 2000) . endometrial tissue (Park et al., 2000) In endometrial hyperplasia, CD9 was also expressed on epithelial cells and its expression intensity was similar to that Discussion of normal endometrial epithelial cells (Table I ). In contrast, the expression of CD9 in endometrial cancer (endometrioid In contrast to that in normal endometrium and endometrial type) appeared to be lower than that in normal endometrium hyperplasia, the expression of CD9 in the endometrial carcin-( Figure 1D -I and Table II) . omas appeared to be reduced. This suggests that the production of CD9 might be altered during carcinogenesis in the human Detection by flow cytometry of CD9 and integrins α 3 , endometrium. It is clear that acquisition of the malignant α 6 and β 1 in cultured RL95-2 and Ishikawa cells phenotype during carcinogenesis is associated with altered Flow cytometry was performed in order to confirm the expresregulation of cellular biological functions, such as cellular sion of CD9 and integrin subunits α 3 , α 6 and β 1 in the proliferation and invasion. In this study, we therefore used endometrial cancer cell lines, RL95-2 (Figure 2) and Ishikawa endometrial cancer cell lines to investigate the effect of anti-(data not shown). Flow cytometry revealed that CD9 was CD9 mAb on cell proliferation and the invasive properties of expressed in RL95-2 (92 Ϯ 7%) and Ishikawa (95 Ϯ 3%) endometrial cancer. Anti-CD9 mAb significantly promoted the cells. Integrins α 3 , α 6 and β 1 were also expressed in RL95-2 number of invading cells in the endometrial cancer cell lines, (76 Ϯ 11, 73 Ϯ 10 and 82 Ϯ 12% respectively) and Ishikawa e.g. RL95-2 and Ishikawa. Since anti-CD9 did not affect cell (92 Ϯ 3, 83 Ϯ 3 and 97 Ϯ 2% respectively) cells (mean Ϯ proliferation, its stimulatory effect on the number of invading SD, n ϭ 3).
cells must have been due to an enhancement of the invasive property itself, rather than to enhanced cell proliferation. These Effect of anti-CD9 on cell invasion and cell proliferafindings suggest that CD9 may be involved in regulating the tion of RL95-2 and Ishikawa cells invasive properties of these cell lines. We could not determine whether the binding of anti-CD9 In the presence of anti-CD9 mAb (ALB-6), the number of invading RL95-2 and Ishikawa cells increased significantly in mAb activates or inhibits the function of the CD9 molecule. 
(D-F) endometrial cancer (endometrioid type G1); (G-I) endometrial cancer (endometrioid type G3). (A) (D) and (G) haematoxylin and eosin staining; (B) (E) and (H) immunostaining with the anti-CD9 monoclonal antibody (mAb). (C) (F) and (I) anti-trinitrophenyl (anti-TNP) mAb (negative controls)
. Intense expression of CD9 was detected on glandular epithelial cells in the endometrium. CD9 expression was reduced in endometrioid type endometrial cancer. Scale bar ϭ 100 µm. , 1997; Mori et al., 1998; Sho et al., 1998 ). In addition, the level or intensity of CD9 expression has been found to be
Fluorescence intensity: -ϭ none; ϩ ϭ weak; ϩϩ ϭ moderate; ϩϩϩ ϭ intense.
inversely correlated with prognosis of the patient and metastatic , 1997) . The transfection of the CD9 gene into several cell lines reportedly suppresses cell motility and metastasis (Ikeyama et al., 1993) . In the human placenta, CD9 was found to be intensely expressed on the extravillous trophoblasts, line known as BeWo cells, suggesting an inhibitory role for the CD9 molecule in trophoblast invasion (Hirano et al. , especially those which have stopped their invasion at the fetomaternal interface (Hirano et al., 1999a) . Moreover, anti-CD9 1999b). Putting these findings together suggests that CD9 might be an important regulator, inhibiting cell invasion in a mAb enhanced the invasion of the human trophoblast-like cell (PIB5) anti-integrin α 6 mAb (OG-1), or anti-integrin β 1 (P4C10) mAb. Histograms showed that the majority of RL95-2 expressed CD9, integrin α 3 , integrin α 6 and integrin β 1 on their cell surface. x axis ϭ relative fluorescence intensity; y axis ϭ cell numbers. Figure 3 . Effects of the anti-CD9 monoclonal antibody (mAb) on the invasion of (A) RL95-2 and (B) Ishikawa cells. The invasion assay was carried out as described in the text in control medium or in the presence of various doses of the anti-CD9 mAb (ALB6) or a control antibody (anti-trinitrophenyl). The results are expressed as a percentage of the mean number of invaded cells in the control and are expressed as the mean Ϯ SEM from five independent experiments. The data were analysed by a one-way analysis of variance, followed by Scheffe's F test for multiple comparisons (*P Ͻ 0.05, **P Ͻ 0.01). y axis ϭ number of invaded cells (% control).
variety of cancers, including endometrial cancer, as well as in integrins may be associated with metastatic nodal spread (Lessey et al., 1995) . Moreover, β 4 integrins have been trophoblasts of the human placenta.
Changed patterns of integrin expression have been reported suggested to affect the invasive properties of human colorectal carcinoma cells (Chao et al., 1996; Daemi et al., 2000) . In in a variety of cancers, which suggests that integrins may be involved in the invasive and metastatic properties of these this study, using flow cytometry, we confirmed that integrins α 3 , α 6 , and β 1 , which we previously found to be associated cancers (Koretz et al., 1990; Zutter et al., 1990; Ruoslahti, 1991) . With respect to endometrial cancer, it has been reported with CD9 in human endometrium (Park et al., 2000) , are expressed on the cell surface of RL95-2 cells. We have also that a decline in integrin expression occurs more frequently in poorly differentiated cancers and that the loss of specific confirmed that CD9 is associated with integrins α 3 , α 6 , and Figure 4 . Effects of the anti-CD9 monoclonal antibody (mAb) (ALB) on RL95-2 cell invasion in the presence of mAb against integrin α 3 (PIB5), α 6 (GoH3) and β 1 (3S3). The results are expressed as a percentage of the number of invaded cells in the control (medium without mAb), and are expressed as the mean Ϯ SEM from five independent experiments. The data were analysed by an one-way analysis of variance, followed by Sheffe's F test for multiple comparisons (*P Ͻ 0.05, **P Ͻ 0.01, NS ϭ not significant). x axis ϭ dose of mAb (mg/ml); y axis ϭ number of invaded cells (% control).
β 1 on RL95-2 cells. Consequently, the effects of blocking mAbs against these integrins on the invasion of RL95-2 cells were examined, and it was found that these mAbs inhibited RL95-2 cell invasion. Since the neutralizing mAbs, which suppress RL95-2 cell invasion, have been reported to block the interaction between integrins and extracellular matrices (Carter et al., 1990; Sonnenberg et al., 1990; Gao et al., 1995) , integrins α 3 , α 6 , and β 1 may be considered to regulate adhesion of RL95-2 cells to extracellular matrices and to regulate their invasion. Next, an investigation of the effects of co-operation between anti-CD9 mAb and anti-integrin mAbs demonstrated that, in the presence of anti-integrin α 3 mAb, anti-CD9 mAb enhanced RL95-2 cell invasion compared with that in the presence of anti-integrin α 3 mAb alone. This indicates that the CD9 molecule regulates RL95-2 cell invasion independent of integrin α 3 . On the other hand, anti-CD9 mAb no longer had any effect on RL95-2 cell invasion following treatment with the anti-integrin α 6 and with β 1 mAbs. These results suggest that the effect of CD9 on RL95-2 cell invasion is directly mediated via integrins α 6 and β 1 , since CD9 is associated with integrins α 6 and β 1 . In addition, we have reported that the inhibitory effect of CD9 on the invasive properties of BeWo cells was mediated by integrin α 5 β 1 (Hirano, 1999b) . Moreover, CD9 has also been reported to be expressed on the human Figure 5 . Western blot analysis of the purified proteins which were granulosa cells in association with integrin α 6 β 1 , suggesting associated with CD9, integrin α 3 and integrin α 6 . The associated the involvement of CD9 in the function of human granulosa proteins were purified from the RL95-2 cell lysate, and then blotted cells in co-operation with this integrin (Takao et al., 1999) .
on the membrane after 12% sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE). Lanes 1, 4 and 5 ϭ purified Therefore, CD9 might be an important regulator of these proteins using anti-CD9 monoclonal antibody (mAb) (TP-82). Lane integrins in a variety of cell systems.
2 ϭ purified proteins using anti-integrin α 3 mAb (11G5). Lanes 3
In the human endometrium, integrins have also been reported and 6 ϭ purified proteins using anti-integrin α 6 mAb (OG-1).
to play important roles in blastocyst implantation (Tabibzadeh Lanes 1-3 ϭ staining with anti-CD9 mAb (SYB-1). Lane 4 ϭ and Babaknia, 1995). We have already reported that CD9 was staining with anti-integrin β 1 mAb (DF5). Lanes 5 and 6 ϭ staining with anti-TNP mAb (negative control). CD9 was detected as a strongly expressed on the epithelial cells in normal human 26.5 kDa protein band in the proteins purified using anti-CD9, antiendometrium throughout the menstrual cycle, including the integrin α 3 and anti-integrin α 6 mAb (Lanes 1-3, arrows). Integrin secretory phase, and was associated with integrins α 3 , α 6 and β 1 was also detected as a 110 kDa protein band in the purified RL95-2 cell line has been used as an in-vitro model of
